Tuesday, October 13, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 9, 2026

Precision Medicine Analysis Report 2026: A $237.28 Billion Market by 2031 - Strategic Pharma-Big-Tech Alliances Speeding Precision Drug Discovery

View original at globenewswire.com
Precision Medicine Analysis Report 2026: A $237.28 Billion Market by 2031 - Strategic Pharma-Big-Tech Alliances Speeding Precision Drug Discovery Dublin, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Asia-Pacific is the fastest-growing region with a 14.12% CAGR

    80% confidence

  • More than 15 FDA clearances since 2024 have tied targeted drugs to specific biomarker tests, widening the addressable patient pool for precision oncology

    80% confidence

  • Next-generation sequencing captured 33.78% of the precision medicine market share in 2025

    80% confidence

  • Guardant Health's Shield blood test detects colorectal cancer with 83% sensitivity in average-risk adults

    80% confidence

  • North America led the precision medicine market with a 47.85% revenue share in 2025

    80% confidence

  • SomaLogic measures 10,000 proteins from a microliter sample, producing high-density data that AI models translate into early disease risk scores

    80% confidence

  • The Precision Medicine market size in 2026 is estimated at USD 125.71 billion, growing from 2025 value of USD 110.68 billion with 2031 projections showing USD 237.28 billion, growing at 13.58% CAGR over 2026-2031

    80% confidence

  • China's Human Genome Project 2 plans to sequence 80 million genomes, creating the world's largest reference panel for variant interpretation

    80% confidence

  • Artificial intelligence and machine learning is the fastest-growing segment at a 17.62% CAGR

    80% confidence

  • Japan has committed to analyze 100,000 cancer genomes under a national program to guide targeted therapy development

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com